



cureCADASIL Patient-Investigator Meeting

Saturday June 29, 2024; 9:00 am to 12:30 pm CDT

at the United Leukodystrophy Foundation Family Conference
in person at the Eaglewood Resort, Itasca, IL and online via Zoom



Agenda

09:00-09:10	Welcome and Introduction - <i>Bertram Kasiske, cureCADASIL President</i>
09:10-10:00	The Power of Patient-Partnered Research in CADASIL <i>Community Advisory Group Panel, moderated by Fanny Elahi</i>
10:00-10:15	The CADASIL Consortium, an Update <i>José Biller</i>
10:15-10:30	National Heart Lung Blood Institute Study, an Update <i>Elisa Ferrante</i>
10:30-10:45	Break
10:45-11:10	Immunotherapy as treatment strategies for CADASIL <i>Helena Karlström</i>
11:10-11:35	Patient stratification and biomarker development for NOTCH3-targeting therapies <i>Julie Rutten</i>
11:35-12:25	Panel Discussion <i>All in person and online participants</i>
12:25-12:30	Announcements: cureCADASIL fall Fundraising campaign! Informal social hour at 5:30 pm for in person attendees

cureCADASIL
Board of
Trustees



Bertram Kasiske
President



Jane Gunther
Past President & Science Officer



Pedro de Lencastre
Secretary



Debra Robinson
Treasurer



Sandra Talbird
Trustee



Vinita Bahl
Trustee




Dr. Fanny Elahi is a physician-scientist in the Departments of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai, New York City. Her research is focused on understanding the link between disease of the brain's small blood vessels and neurodegeneration in CADASIL. Her team is modeling disease using blood and cells from research participants to make discoveries with therapeutic potential and find a cure for CADASIL. In 2022, cureCADASIL and the Elahi Lab at Mount Sinai were awarded a Chan Zuckerberg Initiative, Patient-Partnered Collaborations for Rare Neurodegenerative Disease grant.

cureCADASIL
Community
Advisory
Group



Debaraq Banerjee, PhD



Ki Coale



Andria Burroso




Sheila Connor



Michael Kennedy



Sarah Vadnais-McDaniels



Dr. José Biller is Professor of Neurology and Neurological Surgery and Chair of the Department of Neurology at Loyola University Chicago Stritch School of Medicine. He is the former editor of the Journal of Stroke and Cerebrovascular Diseases. He has published more than 380 peer-reviewed articles and 155 book chapters. He earned his medical degree from the University of the Republic in Montevideo, Uruguay, and post-graduate training in Internal Medicine. He is the recipient of numerous awards for teaching and clinical excellence, and is the site PI in Chicago for the CADASIL Consortium Study.



Dr. Elisa Ferrante, is a Clinical Program Manager/Staff Scientist at the National Heart, Lung and Blood Institute, Translational Vascular Medicine Branch, National Institute of Medicine in Bethesda, Maryland. She graduated from the University of Virginia with a B.S. in 2003 in Mechanical Engineering, M.S. and Ph.D. in 2005 and 2008, respectively, in Biomedical Engineering.



Dr. Helena Karlström is Head and Research group leader at the division of Neurogeriatrics, Department of Neurobiology, Care Science and Society, NVS, Karolinska Institute. She has made important contributions in understanding the mechanisms in Notch3 biology and CADASIL. Most recently her group has developed an active immunotherapy project with encouraging results (Oliveira, et al., EMBO Mol Med, 2023).



Dr. Julie Rutten is a researcher in the Dutch CADASIL Research Group. She has been working on CADASIL together with Dr. Saskia Lesnik Oberstein for more than 10 years. Julie performed the seminal work on the discovery of the high frequency of *NOTCH3* mutations in public whole genome databases, as well as the discovery of the *NOTCH3* mutation position effect in CADASIL.